

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

APPOINTMENT OF CHIEF MEDICAL OFFICER

The board of directors (the “**Board**”) of HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the appointment of Dr. Humphrey Gardner as the Chief Medical Officer (“**CMO**”) of the Company with effect from the date of this announcement.

As the CMO of the Company, Dr. Gardner will be responsible for leading the global clinical development of the Company, including pipeline strategy, clinical development plan & operations and product registration.

Dr. Gardner has more than 30 years of industry experience, achievement and leadership in clinical development and Translational Medicine, including over 20 years of experience in the pharmaceutical industry and over 10 years of experience in academia. Before joining the Company, he served as the chief medical officer at Silicon Therapeutics and the chief of medical oncology at Evelo Biosciences. He also served in leadership roles at Novartis, AstraZeneca and Biogen.

Dr. Gardner obtained his bachelor’s degree in Biochemistry and his medical degree from University of Cambridge, his diploma in Anatomic Pathology from the American Board of Pathology, his master of science degree in Bioinformatics from Brandeis University. He completed his residency in Anatomic Pathology at Beth Israel Hospital, Harvard Medical School, and postdoctoral training at Whitehead Institute, Massachusetts Institute of Technology (MIT).

Dr. Gardner is an expert in oncology, rheumatology and infectious disease. He published approximately one hundred papers in international academic journals and has been an active influential speaker at international conferences. He is also a fellow of the College of American Pathologists, and a member of American Society of Clinical Oncology, and has previously been a member of a variety of professional organizations including the European Society of Clinical Microbiology and Infectious Diseases and the American Association for Clinical Chemistry.

With Dr. Gardner's appointment, the Company will further strengthen its global clinical development capability and continue to advance the global development of its clinical products, including next-generation anti-CTLA-4 antibody HBM4003 and B7H4x4-1BB bispecific antibody HBM7008, whilst enriching the pipeline strategy of the global development of its immunoncology pipeline. The Board believes Dr. Gardner will make valuable contributions to the Group with his extensive medical and clinical experience, and would like to take this opportunity to welcome Dr. Gardner in joining the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman

Hong Kong, 14 April 2022

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Mr. Xiaoxiang Chen as executive directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive directors.